ES2353814T3 - Proteinas n-glicosiladas recombinantes de celulas procariotas. - Google Patents

Proteinas n-glicosiladas recombinantes de celulas procariotas. Download PDF

Info

Publication number
ES2353814T3
ES2353814T3 ES06753552T ES06753552T ES2353814T3 ES 2353814 T3 ES2353814 T3 ES 2353814T3 ES 06753552 T ES06753552 T ES 06753552T ES 06753552 T ES06753552 T ES 06753552T ES 2353814 T3 ES2353814 T3 ES 2353814T3
Authority
ES
Spain
Prior art keywords
proteins
recombinant
cells
procedural
glycosilated proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06753552T
Other languages
English (en)
Inventor
Markus Aebi
Umesh Ahuja
Michael Kowarik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ETH Zurich
Original Assignee
ETH Zurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ETH Zurich filed Critical ETH Zurich
Application granted granted Critical
Publication of ES2353814T3 publication Critical patent/ES2353814T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para producir proteínas glicosiladas N-enlazadas, que comprende: a) proporcionar ácidos nucleicos que codifican al menos una proteína diana recombinante, b) insertar ácidos nucleicos que codifican una o más de las secuencias de aminoácidos de consenso N-glicosiladas y optimizadas siguientes: D/E - X - N - Z - S/T en que X y Z pueden ser cualquier aminoácido natural salvo Pro, en dichos ácidos nucleicos de a), c) proporcionar un organismo recombinante, preferiblemente un organismo procariótico, que comprende ácidos nucleicos que codifican (i) un operón pgl funcional de Campylobacter spp., preferiblemente C. jejuni, y (ii) al menos una proteína diana recombinante codificada por los ácidos nucleicos que resultan de la operación b), y d) cultivar el organismo recombinante de un modo adecuado para la producción y N-glicosilación de la(s) proteína(s) diana.
ES06753552T 2005-05-11 2006-05-10 Proteinas n-glicosiladas recombinantes de celulas procariotas. Expired - Lifetime ES2353814T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11

Publications (1)

Publication Number Publication Date
ES2353814T3 true ES2353814T3 (es) 2011-03-07

Family

ID=37396912

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10179208.3T Expired - Lifetime ES2535084T3 (es) 2005-05-11 2006-05-10 Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ES14199949T Expired - Lifetime ES2703061T3 (es) 2005-05-11 2006-05-10 Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ES06753552T Expired - Lifetime ES2353814T3 (es) 2005-05-11 2006-05-10 Proteinas n-glicosiladas recombinantes de celulas procariotas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES10179208.3T Expired - Lifetime ES2535084T3 (es) 2005-05-11 2006-05-10 Proteínas N-glicosiladas recombinantes procedentes de células procariotas
ES14199949T Expired - Lifetime ES2703061T3 (es) 2005-05-11 2006-05-10 Proteínas N-glicosiladas recombinantes procedentes de células procariotas

Country Status (19)

Country Link
US (3) US8753864B2 (es)
EP (3) EP2311972B1 (es)
JP (3) JP5356807B2 (es)
KR (2) KR101408653B1 (es)
CN (2) CN101360831B (es)
AT (1) ATE483027T1 (es)
AU (1) AU2006245969B8 (es)
CA (1) CA2607595C (es)
CY (1) CY1116285T1 (es)
DE (1) DE602006017207D1 (es)
DK (2) DK1888761T3 (es)
ES (3) ES2535084T3 (es)
HK (1) HK1205193A1 (es)
HR (1) HRP20150312T1 (es)
IL (2) IL187293A (es)
PL (1) PL2311972T3 (es)
PT (2) PT1888761E (es)
SI (1) SI2311972T1 (es)
WO (1) WO2006119987A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
KR20070110402A (ko) * 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
WO2009089154A2 (en) 2008-01-03 2009-07-16 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
SI2257307T1 (sl) * 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
CN102365359B (zh) * 2009-03-27 2014-10-29 瑞士联邦苏黎世技术大学 呈递空肠弯曲杆菌n-聚糖或其衍生物的肠沙门氏菌
NO2501406T3 (es) * 2009-11-19 2018-05-19
CA2789505C (en) 2010-02-11 2017-12-05 The Governors Of The University Of Alberta N-linked glycan compounds
WO2011138361A1 (en) * 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
WO2012027850A1 (en) * 2010-09-03 2012-03-08 Christine Szymanski Peptide containing multiple n-linked glycosylation sequons
CA2847621A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
HUE038915T2 (hu) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh MDR E. colira fajlagos antitest
US9931392B2 (en) 2013-01-18 2018-04-03 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2970128B1 (en) 2013-03-15 2019-12-04 Asieris Pharmaceutical Technologies Co., Ltd. Base addition salts of nitroxoline and uses thereof
CA2907795C (en) * 2013-04-05 2023-09-05 The Governors Of The University Of Alberta Campylobacter vaccine
BR112016007727A8 (pt) * 2013-10-11 2018-01-30 Glycovaxyn Ag célula hospedeira, e, método para produzir uma proteína n-glicosilada.
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
MX378857B (es) * 2014-04-17 2025-03-10 Glaxosmithkline Biologicals Sa Celulas huespedes modificadas y usos de las mismas.
AR104469A1 (es) 2014-08-08 2017-07-26 Glycovaxyn Ag Células huésped modificadas para su uso en producción de bioconjugados
SI3240895T1 (sl) * 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN110520153B (zh) * 2017-01-27 2024-04-02 佛罗里达大学研究基金公司 在禽类中控制肠道沙门氏菌和减少弯曲杆菌的食品安全疫苗
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
JP7551618B2 (ja) 2018-12-12 2024-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
EP3908669A4 (en) 2019-01-11 2023-05-03 Northwestern University SYNTHESIS OF BIOCONJUGATED VACCINES IN PROKARYOT CELL LYSATE
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
WO2021081485A1 (en) 2019-10-25 2021-04-29 Northwestern University Cell-free extract preparation protocol for enrichment of membrane vesicles and increased glycoprotein yields
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
CA3185719A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230226175A1 (en) 2020-06-25 2023-07-20 Glaxosmithkline Biologicals Sa Modified exotoxin a proteins
PE20231385A1 (es) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc Composiciones de vacunas multivalentes y usos de las mismas
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途
MX2023011697A (es) 2021-04-01 2023-10-19 Janssen Pharmaceuticals Inc Produccion de bioconjugados o18 de e. coli.
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20260051063A (ko) * 2023-08-09 2026-04-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
KR20260052081A (ko) 2023-08-09 2026-04-17 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 단백질
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A2 (en) 1999-03-02 2004-03-24 Human Genome Sciences, Inc. Engineering intracellular sialylation pathways
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP2028275A3 (en) 2000-06-30 2009-05-06 VIB vzw Protein glycosylation modification in pichia pastoris
DE10113573A1 (de) * 2001-03-20 2002-02-28 Messer Griesheim Gmbh Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen
DK1481057T3 (da) 2002-03-07 2006-05-15 Eidgenoess Tech Hochschule System og fremgangsmåde til fremstilling af rekombinante glycosylerede proteiner i en prokaryot vært
JP4727927B2 (ja) 2002-03-07 2011-07-20 アイトゲネシシェ・テッヒニシェ・ホーホシューレ・チューリッヒ 原核宿主における組換えグリコシル化タンパク質産生のためのシステムおよび方法
CN1671722A (zh) * 2002-08-01 2005-09-21 加拿大国家研究院 弯曲菌的聚糖和糖肽

Also Published As

Publication number Publication date
SI2311972T1 (sl) 2015-08-31
PT2311972E (pt) 2015-05-13
AU2006245969B8 (en) 2011-08-25
US8753864B2 (en) 2014-06-17
AU2006245969A1 (en) 2006-11-16
IL226857A0 (en) 2013-07-31
DK2311972T3 (en) 2015-04-27
CN101360831A (zh) 2009-02-04
US20160326563A1 (en) 2016-11-10
KR20140019482A (ko) 2014-02-14
WO2006119987A3 (en) 2007-03-08
CA2607595A1 (en) 2006-11-16
JP5687637B2 (ja) 2015-03-18
ES2703061T3 (es) 2019-03-06
ATE483027T1 (de) 2010-10-15
HK1156983A1 (en) 2016-11-25
EP1888761B1 (en) 2010-09-29
AU2006245969B2 (en) 2011-06-02
JP5827303B2 (ja) 2015-12-02
IL187293A0 (en) 2008-04-13
CN103396478B (zh) 2016-09-28
JP2012100678A (ja) 2012-05-31
IL187293A (en) 2013-06-27
CN101360831B (zh) 2013-07-10
US9551019B2 (en) 2017-01-24
IL226857A (en) 2017-08-31
WO2006119987A2 (en) 2006-11-16
HK1113588A1 (en) 2008-10-10
JP2014042533A (ja) 2014-03-13
PL2311972T3 (pl) 2015-08-31
CA2607595C (en) 2018-11-27
JP2008539743A (ja) 2008-11-20
EP2311972A1 (en) 2011-04-20
DK1888761T3 (da) 2010-11-01
HRP20150312T1 (hr) 2015-07-31
HK1205193A1 (en) 2015-12-11
US20140323700A1 (en) 2014-10-30
CN103396478A (zh) 2013-11-20
EP2853600A1 (en) 2015-04-01
US20100062484A1 (en) 2010-03-11
EP1888761A2 (en) 2008-02-20
ES2535084T3 (es) 2015-05-05
EP2311972B1 (en) 2015-01-21
CY1116285T1 (el) 2017-02-08
KR101524636B1 (ko) 2015-06-03
JP5356807B2 (ja) 2013-12-04
DE602006017207D1 (de) 2010-11-11
KR101408653B1 (ko) 2014-06-17
PT1888761E (pt) 2011-01-03
KR20080048990A (ko) 2008-06-03
EP2853600B1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
CY1116285T1 (el) Ανασυνδυασμενες ν-γλυκοζυλιωμενες πρωτεϊνες απο προκαρυωτικα κυτταρα
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
CY1117401T1 (el) Πρωτεϊνες συντηξης αλβουμινης
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
ATE530643T1 (de) Säureaktive fungale protease
NZ591415A (en) Haemophilus influenzae type B
PH12012502272A1 (en) Biological materials related to her3
MX2009012650A (es) Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos.
CY1108571T1 (el) Διεργασια για την παραγωγη και τον καθαρισμο ερυθροποιητινης
EA200501798A1 (ru) Новые пептиды, которые связываются с рецептором к эритропоэтину
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
EA201100071A1 (ru) Новые композиции и способы
WO2006038908A3 (en) Ancestral and cot viral sequences, proteins and immunogenic compositions
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
ATE543833T1 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
WO2006017355A3 (en) Improved aprotinin variants
WO2006047728A3 (en) Bmp gene and fusion protein
TW200724679A (en) Treatment of disease using an improved regulated expression system